Dabigatran Is Not a Direct Xa Inhibitor
نویسندگان
چکیده
منابع مشابه
A New Oral Direct Factor Xa Inhibitor
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملEdoxaban: a new oral direct factor xa inhibitor.
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملDabigatran (Rendix): A Promising New Oral Direct Thrombin Inhibitor
INTRODUCTION Thromboembolic events are significant sources of morbidity and mortality that often necessitate long-term anticoagulation therapy. Although a variety of effective anticoagulants exist, heparins, heparinoids, and most direct thrombin inhibitors are available as injectable formulations and are typically unsuitable for long-term use. Warfarin (Coumadin, Bristol-Myers Squibb), an oral ...
متن کاملRe-initiation of dabigatran and direct factor Xa antagonists after a major bleed☆,☆☆,★
Direct oral anticoagulants (DOACs) are a relatively recent addition to the oral anticoagulant armamentarium, and provide an alternative to the use of vitamin K antagonists such as warfarin. Regardless of the type of agent used, bleeding is the major complication of anticoagulant therapy. The decision to restart oral anticoagulation following a major hemorrhage in a previously anticoagulated pat...
متن کاملRivaroxaban: an oral direct inhibitor of factor Xa.
PURPOSE The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban are reviewed. SUMMARY Rivaroxaban, the first oral, direct factor Xa (FXa) inhibitor to reach Phase III trials, inhibits thrombin generation by both the intrinsic and the tissue factor pathways. It has shown predictabl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2012
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2012.02.006